Lates News

Every AI Express News, Dongwu Securities issued a research report on April 7th, giving an "buy" rating to Kelun Pharmaceutical (002422.SZ). The reasons for the rating mainly include: 1) Short-term pressure on large infusions, structural upgrading is expected to support stability; 2) Non-infusion preparations, antibiotic intermediates and raw materials remain stable; 3) The innovative pipeline has entered the realization period. (Daily Economic News)